An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.
about
The molecular basis of HIV entryStructures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common ThemeEstimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusionRapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entrySelection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HKinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1How HIV changes its tropism: evolution and adaptation?Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses.Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entryMathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections.
P2860
Q26863686-BCE3A78D-C11C-46E4-97E1-E535E56F8ADCQ27487974-B8EA9AC9-186A-474A-B0B2-874BB09CA2E2Q28478341-A2043808-380C-4C5E-B7D3-E4C69F007EEEQ33676520-27894484-0D25-4485-B9D6-DE45736A7004Q34610959-C0F4F1F2-0BF9-44C8-8D08-2680AF5A5CF7Q34875765-372667F1-C5B4-451C-BDF7-A025520538A1Q35599288-B9A43667-965E-4C01-A2E0-57E5126CF567Q35974165-99515778-CBFD-411C-9899-88D7C5A3A176Q36078450-B9F4B845-79B2-44F8-A643-938B421FC743Q37230002-3D25EF90-96E7-4616-9258-F45F88A312D7Q37263225-D688336D-AFF4-4156-B8D0-8337C29B2FFFQ37348882-8F2F8BAD-CBE7-4075-A3FA-3414EE7F86F0Q37452124-7F21D5A8-AB77-4A20-A38C-E4B2ABC68DBEQ37713831-5CBFB68C-A204-449E-80E3-C16ABCA925A4Q38076139-F3544350-B2FA-447D-B0F8-C46BC0AA6865Q39870010-62A02BCC-E0F2-4A7B-879A-05500ED96752Q40376100-D4844036-62BA-4FE6-B4F4-DC2EA9A6F42AQ41752911-9757EB39-6594-425A-9A9D-4E6C1D6F4C16
P2860
An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
An allosteric rheostat in HIV- ...... mes diverse entry limitations.
@en
type
label
An allosteric rheostat in HIV- ...... mes diverse entry limitations.
@en
prefLabel
An allosteric rheostat in HIV- ...... mes diverse entry limitations.
@en
P2093
P2860
P1476
An allosteric rheostat in HIV- ...... mes diverse entry limitations.
@en
P2093
David Kabat
Emily J Platt
James P Durnin
Ujwal Shinde
P2860
P356
10.1016/J.JMB.2007.09.016
P407
P577
2007-09-12T00:00:00Z